4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-020265
PRESIDENT AND CEO sold 12,000 shares at an average $24.92 ($299,073)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kintz Samuel · PRESIDENT AND CEO
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-07-25 | Sale : show line 1 in the form 10b5-1 | −3,793 | $24.53 | $93,042 | 1,071,732 | I |
| 2024-07-25 | Sale : show line 2 in the form 10b5-1 | −8,164 | $25.10 | $204,920 | 1,063,568 | I |
| 2024-07-25 | Sale : show line 3 in the form 10b5-1 | −43 | $25.83 | $1,111 | 1,063,525 | I |
| Open-market sales · 12,000 sh · avg $24.92 · $299,073 | ||||||
Loading xslF345X05/form4-07292024_090754.xml…